Moderna's cancer vaccine passed a key trial, yet its stock remains volatile. The company's market value swung from $200 billion in 2021 to $10 billion last year as vaccine demand faded. Now, investors face uncertainty: while the cancer vaccine shows promise, the stock price already reflects massive future success.
Analysts warn that expectations may be too high, leading to potential whiplash for investors. Moderna's future hinges on whether its pipeline can deliver beyond Covid-19. The drugmaker must prove its broader portfolio can sustain growth, or risk further declines.
With the stock priced for perfection, any setbacks could trigger sharp sell-offs.
Source: Wall Street Journal Markets · Summarized by HeadlinesBriefing